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Genetic studies of patients with the nevoid basal cell
carcinoma syndrome have led to the recognition of
the importance of the hedgehog signaling pathway in
the development of basal cell carcinomas of the skin.
Although hedgehog signaling is known to be important
in hair follicle development, the function of this path-
way in adult skin and the mechanism by which activa-
tion of this pathway leads to basal cell carcinoma
development remain to be established. The Gli1 family
of transcription factors mediates hedgehog signaling
in mammalian cells and we have shown in previous
studies that Gli1 mRNA is differentially expressed in
basal cell carcinomas. Using antibodies to epitopes on
the N and C terminal regions of Gli1 we show now
that Gli1 protein is present in basal cell carcinomas and
that the protein is mainly localized to the cytoplasmic
compartment. Focal nuclear staining was seen in a
small number of basal cell carcinomas with the C
terminal antibody which suggest that nuclear localiz-
Genetic studies of patients with the nevoid basal cellcarcinoma syndrome, which predisposes affectedindividuals to the development of multiple basal cellcarcinomas (BCC), have led to the identification ofthe human homolog of the Drosophila gene Patched
as the gene responsible for this syndrome (Hahn et al, 1996; Johnson
et al, 1996). Although loss of heterozygosity analysis of both sporadic
and familial BCC of the skin indicate that Patched (Ptc) is a tumor
suppressor gene (Quinn et al, 1994), both the function of this gene
in normal skin and the mechanism by which inactivation of Ptc
leads to BCC development remain to be established. Activation of
hedgehog (Hh) signaling in Drosophila is associated with activation
of specific target genes including wingless and patched, and the
repression of others including hedgehog. These changes require the
presence of a transcription factor called Cubitus interruptus (Ci)
which shows significant homology to the Gli family of transcription
factors in vertebrates (Von Ohlen et al, 1997).
We and others have shown using reverse transcriptase–polymerase
chain reaction (PCR) that Gli1 but not Gli3 is differentially
expressed in BCC (Dahmane et al, 1997; Green et al, 1998). The
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ation is not dependent on loss of the C terminus of
Gli1 due to proteolysis. Strong Gli1 immunostaining
was seen in the outer root sheath keratinocytes of
some hair follicles, a subpopulation of mesenchymal
cells in the vicinity of the bulge region of adult hair
follicles and the dermal sheath cells of developing hair
follicles. Quantitation of Gli1 mRNA in basal cell
carcinomas using northern blot analysis indicates that
Gli1 is highly expressed in basal cell carcinomas. This
suggests that the lower intensity of Gli1 immuno-
staining in basal cell carcinoma islands relative to outer
root sheath keratinocytes is not simply a reflection of
differences in gene expression. The continued expres-
sion of Gli1 in adult hair follicles and in the mesen-
chyme of adult human skin suggest that Hh signaling
may play a part in hair cycling and in epidermal
mesenchymal interactions important in normal skin
maintenance. Key words: basal cell carcinoma/Gli/hair
follicle/hedgehog/methylation/patched/promoter/skin can-
cer/stem cell. J Invest Dermatol 113:595–599, 1999
localization of Gli1 transcripts to BCC tumor islands using in situ
hybridization excludes the possibility that the change in Gli1
expression is due to alterations in the adjacent tumor stroma and
suggests that Hh signaling in keratinocytes is mediated by Gli1.
The basis for the accumulation of Gli1 transcripts in BCC that
accompanies Ptc inactivation is not known. The observation that
forced expression of Hh in keratinocytes in vitro is not accompanied
by the accumulation of Gli1 transcripts suggests that changes in
Gli1 expression may not be an inevitable consequence of Hh
signalin.1 In Drosophila Hh signaling is mediated by proteolytic
processing of Ci that is not accompanied by changes in Ci
mRNA levels. Full length Ci is found primarily in the cytoplasmic
compartment and the shorter cleaved fragment which includes the
DNA binding domain is localized almost exclusively to the nucleus.
The cleaved form of Ci appears to function as a transcriptional
repressor and its production is decreased in the presence of Hh
(Aza-Blanc et al, 1997). Although there is no direct evidence to
date that Gli1 protein activity in mammalian cells is regulated by
protein cleavage, immunohistochemical analysis of the intracellular
distribution of Gli1 using a polyclonal antibody to the Gli DNA
1Oro AE, Fan H, Khavari PA, Scott MP: Towards development of an
in vitro model of human BCC formation. J Invest Dermatol 110:500,
1998 (abstr.)
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binding domain has shown that Gli protein is localized to the
cytoplasmic compartment in BCC but is found in the nucleus in
COS cells transfected with a Gli1 construct (Dahmane et al, 1997).
The significance of this observation with respect to regulation of
Gli1 function has not been established.
In order to investigate further Hh signaling in human skin we
have investigated Gli1 protein expression in BCC and normal skin
by immunohistochemistry using antibodies to the N and C terminal
domains. We have also quantitated the changes in Gli1 mRNA
expression that accompany BCC development and looked for
alterations in the methylation status of the Gli1 promoter in
association with BCC development.
MATERIALS AND METHODS
Tissue samples Normal human scalp skin was obtained as excess tissue
from unrelated surgical procedures and either fixed in formalin and paraffin
embedded or frozen in OCT. BCC samples used were either formalin-
fixed paraffin-embedded tissue from the pathology archives for patients
with BCC or frozen tumor samples obtained at the time of surgery. Clinical
diagnosis was confirmed in all cases by histologic examination.
Antibodies and synthetic peptides Goat polyclonal IgG antisera sc-
6152 and sc-6153 were used to stain for human Gli1 The antibodies as
well as the corresponding immunogenic peptides were obtained from Santa
Cruz Biotechnology (Santa Cruz, CA). s-6152 recognizes an epitope
corresponding to an amino acid sequence at the carboxy terminal of human
Gli1. s-6153 recognizes an epitope corresponding to an amino acid
sequence at the amino terminal. Both antibodies are specific for Gli1 and
do not cross-react with Gli-3 according to the data provided by the
manufacturer.
Immunohistochemistry Goat polyclonal antibodies were used to spe-
cifically detect Gli1 protein expression in formalin-fixed tissue samples.
Antibody localization was by avidin–biotin peroxidase staining of histologic
sections from normal human scalp and from patients with BCC. For
immunohistochemistry formalin-fixed tissue samples were sectioned at
4 µm, deparaffinized, and rehydrated through a graded series of ethanol.
After blocking of endogenous peroxidase activity with 3% hydrogen
peroxide in methanol for 10 min, sections were blocked with Tris buffer,
pH 7.6, containing serum and incubated with 1 : 500 dilution of either
anti-Gli1 N or anti-Gli1 C, or rabbit serum as a negative control over
night at 4°C. Following two buffer washes of the sections, the secondary
biotinylated rabbit anti-goat antibody conjugated to biotin (Vector Labora-
tories, Burlingame, CA) was applied for overnight incubation at 4°C. After
the secondary anti-serum, the sections were incubated with AB Complex
(Vector Laboratories) for 2 h at room temperature, and reaction product
was visualized using diaminobenzidine as a chromogenic substrate. Finally,
the sections were briefly counterstained with Gills hematoxylin.
For immunofluorescence labeling frozen sections from BCC and normal
skin were cut at 7 µm, fixed in methanol at –20°C for 2 min, rinsed with
Tris-buffered saline, blocked with rabbit serum, and reacted with the anti-
Gli1N and C terminus antibody 1:500 overnight at 4°C. The secondary
antibody (fluorescein isothiocyanate-conjugated rabbit anti-goat immuno-
globulins, Dako, Carpinteria, CA) diluted at 1:100 was applied for 6 h.
The sections were then rinsed in Tris-buffered saline and counterstained
with propidium iodide.
RNA isolation and northern analysis Polyadenylated RNA was
isolated from BCC, normal skin samples, cultured keratinocytes, and the
Tera-1 cell line by the acid guanidinium thiocyanate/phenol/chloroform
method (RNAce Total Pure Kit, Bioline Ltd, London, U.K.) and a
Dynabeads mRNA Purification kit (Dynal AS, Oslo, Norway). One
microgram of polyadenylated RNA extracted from 20 µm of total RNA
was size fractionated on 1% formaldehyde-agarose gels and then transferred
on to nylon membrane (Hybond-XL, Amersham Pharmacia Biotech,
Amersham, U.K.). Membranes were then hybridized using the PCR-
generated Gli1 specific probe. Transcript size was estimated by comparison
with RNA molecule size standard (GIBCO/BRL, Life Technologies,
Paisley, U.K.). Hybridization was done overnight at 42°C. Filters were
washed in 2 3 sodium citrate/chloride buffer and 0.1% sodium dodecyl
sulfate at room temperature for 5 min twice followed by a further wash
in 1 3 sodium citrate/chloride buffer and three washes in 0.1% sodium
dodecyl sulfate at room temperature. The final two washes were in 0.1 3
sodium citrate/chloride buffer and 0.1% sodium dodecyl sulfate at 50°C.
Methylation analysis of the Gli1 promoter PCR using primers based
on the published sequence of the human Gli1 promoter (accession number)
was used to amplify a 271 bp fragment from the 59 UTR of the Gli1 gene
which flanks a CpG rich region (Liu et al, 1998). Primer sequences
used were:
F primer 59 CTTGGGGGTGAGACATTAGA AC 39 position 1151–
1172
R primer 59 CAGTCCCCACCTTTCAGAAAC 39 position 1412–1432
Purified PCR product was labeled by random priming and hybridized
to southern blots of blood, normal skin, and BCC DNA digested with
methylation sensitive restriction enzymes. Filters were washed to a final
stringency of 0.1 3 sodium citrate/chloride buffer at 65°C and exposed
for 2–3 d. Hybridization signal was visualized using a Phosphorimager
(Molecular Dynamics, Sunnyvale, CA).
RESULTS
Gli1 protein is expressed in BCC In order to determine if the
Gli1 antibodies detected increased Gli1 protein in BCC and look
for evidence of Gli1 processing in BCC we carried out an
immunohistochemical analysis of Gli1 protein distribution in BCC
using polyclonal antibodies to the N and C terminal domains.
Immunostaining with both antibodies demonstrated positive stain-
ing of BCC tumor islands (Fig 1a). All BCC examined were
positive for at least one of the antibodies. Eleven of 13 BCC
examined stained with the C terminal antibody and eight of 12
with the N terminal. Staining was consistently stronger in the BCC
with the C terminal antibody. In most BCC immunostaining was
predominately cytoplasmic with little or no nuclear staining. In
two BCC we observed focal areas of nuclear staining within BCC
tumor islands with the C terminal antibody (Fig 1b). Both of these
BCC stained showed cytoplasmic staining with the N terminal
antibody. In one BCC we observed nuclear staining with both the
C and N terminal antibodies. Interestingly in this patient we also
observed nuclear staining within the outer root sheath (ORS) in
the same section. The pattern of staining identified in BCC was
the same for both frozen and formalin fixed specimens and the
staining within BCC could be blocked by preabsorption with the
appropriate blocking peptide.
Gli1 is expressed in normal skin in the ORS of anagen hair
follicles and in a subpopulation of mesenchymal cells in
the vicinity of the hair follicle bulge During the course of
experiments investigating Gli1 protein expression in BCC we
observed immunostaining of both mesenchymal and epithelial
elements of some hair follicles. Both the N and C terminal
antibodies selectively stained the cytoplasm of cells in the ORS of
some hair follicles (Fig 2a, b). In addition to ORS staining, the C
terminal antibody selectively stained a subpopulation of mesenchy-
mal cells adjacent to the ORS basal layer below the sebaceous
gland duct at the attachment site of the arrector pili muscles
(Fig 3a). In some follicles positive immunostaining extended from
this region along the mesenchymal sheath. Staining of the dermal
papilla was not seen with either antibody. The ORS staining and
mesenchymal staining was considerably more intense than that seen
in BCC islands in the same section (Fig 1). The staining seen in
both the ORS cells and in the mesenchymal cells was exclusively
cytoplasmic in all but one of the sections examined and was
inhibited by preabsorption with the appropriate blocking peptide.
A similar staining pattern was seen in adult scalp biopsies obtained
from several different individuals. Immunostaining of human fetal
skin samples with the C terminal antibody also revealed staining
of mesencyhmal elements of the developing hair follicle. The
mesenchymal staining appeared to be polarized to the same side of
the follicle in sections where hair follicles were sectioned in the
same plane (Fig 3b).
BCC development is associated with a marked increase in
Gli1 mRNA levels Although we have shown previously that
Gli1 mRNA is present in BCC but not normal skin using reverse
transcriptase–PCR, the relative abundance of Gli1 transcripts in
BCC is not known. In view of the differences in the intensity of
Gli1 immunostaining between BCC and the ORS we have
investigated the level of expression of Gli-1 in BCC using northern
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Figure 1. Immunohistochemistry showing positive immunostain-
ing for Gli1 in BCC. Immunohistochemical staining was carried out
with antibody s6152 directed against a C terminal epitope of Gli1 (a)
shows positive staining in the BCC with negative staining of the adjacent
normal epidermis. The staining is cytoplasmic. Scale bar: 100 µm. (b) High
power view of foci of Gli positive cells within a BCC which shows nuclear
staining. Scale bar: 10 µm.
Figure 2. Immunohistochemistry showing positive staining of the
ORS with antibodies (a) s6152 and (b) s6153 which are directed
against the C terminal and N terminal epitope of Gli1, respectively.
Staining is cytoplasmic and both antibodies stain the same area of the
follicle. Scale bar: 100 µm.
Figure 3 Immunohistochemistry showing positive staining of a
subpopulation of mesenchymal cells of the hair follicle with
antibody s6152 directed against a C terminal epitope of Gli1. (a)
shows staining in adult human skin. Extension of the positive staining
along the mesenchymal sheath is seen in some follicles. (b) In fetal skin
15 wk gestation positive staining is seen in the mesenchymal cells adjacent
to the follicle. No epidermal staining is seen in the developing fetal follicle.
Scale bar: 100 µm.
Figure 4. Comparison of Gli1 mRNA expression in BCC, normal
skin, cultured keratinocytes, and Tera-1 line. Poly(A) RNA isolated
from BCC (lanes 1–3), normal skin (lanes 4–5), 1° keratinocytes and Tera-
1 line was separated on 1% agarose gel, blotted on to Hybond-XL and
sequentially hybridized with Gli1 (5 d exposure) and B-actin (5 h exposure).
Strong Gli-1 signal is seen in all three BCC but not in normal skin. Weaker
signal is also seen in the Tera-1 line.
blot analysis using the PCR generated Gli1 specific probes that we
have used previously for in situ hybridization (Fig 4). Our probe
detected a single 4 kb hybridizing band in BCC but not normal
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Figure 5. (A) Schematic map of Gli1 promoter and position CpG island and PCR generated probe. (B) Southern blot analysis of leukocyte DNA
digested with Eag1, MspI, HpaII, and SacI. A single hybridizing band is seen in each lane. The HpaII fragment is identical in size to the MspI fragment
indicating that the CpG region in the promoter is unmethylated. (C) Southern blot analysis of DNA from normal skin and BCC digested with MspI and
HpaII. A strong hybridizing 900 bp band identical to that seen in the leukocyte DNA is seen in both HpaII and MspI digests in both BCC and normal
skin. The identical pattern of hybridization in the HpaII and MspI digests indicate that the Gli1 promoter is not methylated in normal skin and BCC.
skin which corresponds with the previously reported Gli1 transcript
size (Kinzler et al, 1988). Gli1 was highly expressed in all three
BCC studied. Gli1 was not detected in normal skin or in mRNA
isolated from cultured keratinocytes. In order to correct for
loading differences the filter was hybridized with β-actin probe.
Quantitation of hybridization signal corrected for loading differences
indicated that there is a more than 40-fold increase in transcript
abundance in the BCC compared with normal skin. This compares
with only a 4-fold increase in the teratocarcinoma line Tera-1,
which is a well characterized Gli1 expressing line.
Alterations in Gli1 expression in BCC is not accompanied
by changes in DNA promoter methylation Gli1 is not
normally expressed in adult tissues. The Gli1 promoter has recently
been cloned and the presence of a CpG island in the promoter has
led to speculation that Gli1 expression in adult tissues may be
repressed by DNA methylation (Liu et al, 1998). In order to
determine if alterations in Gli1 expression in BCC are associated
with changes in methylation of the Gli1 promoter we generated a
probe from the 59 untranslated region of the Gli1 gene and
used this to investigate the methylation status of Gli1 in normal
leukocytes, normal skin and BCC by southern blot analysis. The
probe used detected a 1.45 kb SacI fragment which is consistent
with published information on the genomic structure of the
Gli1 promoter (Fig 5a). The Gli1 promoter was found to be
unmethylated in leukocytes as evidenced by the identically sized
hybridizing fragments in MspI and HpaII digests (Fig 5b). The
promoter was also found to be unmethylated in all of the normal
skin and BCC samples examined (Fig 5c). These findings indicate
that Gli1 expression in BCC is not accompanied by alterations in
DNA methylation of the promoter.
DISCUSSION
A number of lines of evidence indicate that Hh signaling pathway
plays a key part in both normal hair follicle formation and in the
development of the common human skin cancer, BCC. In a
previous study using reverse transcriptase–PCR and 35S in situ
hybridization we showed that Gli1 mRNA is expressed in BCC
but not normal interfollicular skin. Although the basis for the
accumulation of Gli1 transcripts in BCC that accompanies Ptc
inactivation is not known, there is some evidence to suggest that
the increased Gli1 expression may not be directly mediated by Hh
signaling. In Drosophila, Hh signaling is regulated by proteolytic
cleavage of the Gli homolog Ci. Although there is no direct
evidence to date that Gli1 protein activity in mammalian cells is
regulated by protein cleavage, immunohistochemical analysis of the
intracellular distribution of Gli1 using a polyclonal antibody to the
DNA binding domain has shown that Gli1 protein is localized to
the cytoplasmic compartment in BCC but is found in the nucleus
in COS cells transfected with a Gli1 construct (Aza-Blanc et al, 1997)
Immunohistochemical analysis of BCC with antibodies to the
N and C terminal domains in this study has shown that Gli1
protein can be detected in BCC using these antibodies. The staining
pattern seen with both antibodies was not identical. Positive
immunostaining was seen less frequently in BCC with the N
terminal compared with the C terminal antibody. The immuno-
staining with the C terminal antibody also gave stronger staining
in the samples that were positive for both antibodies. Although the
antibodies used gave different staining patterns in the BCC islands,
both antibodies stained the ORS of some hair follicles which
suggests that the difference in staining within the BCC may be
due to epitope masking of the N terminal epitope in tumors. In
most of the BCC examined, the immunostaining was cytoplasmic
which is consistent with a previous report using a polyclonal
antibody to the DNA binding domain of Gli1 (Dahmane et al,
1997). In two BCC we observed small areas within the BCC
islands which showed nuclear staining with the C terminal antibody.
In one BCC we identified strong nuclear staining with both
antibodies. In Drosophila the full length active form of Ci is
sequestered in the cytoplasm by tethering to microtubules, and can
undergo proteolytic cleavage to produce a truncated N terminal
fragment which localizes to the nucleus. In the presence of hh
signaling, proteolytic processing is inhibited and the full length
active form is released which leads to activation of hh target genes.
Given that Gli1 acts as a transcription factor, our finding that most
BCC show cytoplasmic staining suggest that the intracellular
distribution of Gli1 may be important in controlling Gli1 activity
in keratinocytes. Our finding of nuclear staining with the C
terminal antibody in some BCC in this work and that C terminal
epitope tagged Gli1 localizes to the nucleus in transfected human
cells (unpublished data) indicates that nuclear localization of Gli1 is
not dependent on cleavage of the C terminal region in human cells.
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In addition to detecting Gli1 protein in BCC we have also
found Gli1 protein in the ORS of normal human hair follicles
with both antibodies. Although there is no published information
on Gli1 protein distribution in adult human or murine skin, the
positive staining in the ORS is in the same compartment of the
follicle as ptc-1 in murine skin localized using a β-galactosidase
reporter fused to the ptc-1 locus.1 Given that ptc-1 is transcrip-
tionally regulated by Gli1, our observation of ORS staining is
consistent with the concept that ptc-1 is a transcriptional target of
Gli1 and therefore shows a similar distribution. Our finding of
positive immunostaining with the antibody to the C-terminal Gli1
epitope in a subpopulation of mesenchymal cells near the bulge
region of the hair follicle is a novel finding and warrants further
investigation given that it has been proposed that this region
contains putative epidermal stem cells (Cotsarelis et al, 1990).
Although we cannot exclude the possibility that the antibody is
detecting a cross-reacting epitope on another protein we think this
is unlikely for two reasons. First, Gli1 gene expression during
hair follicle development is observed in both the epidermal and
mesenchymal compartment and Gli1 expression by day 18.5 days
post coitum in mice is expressed in the dermal sheath (St-Jacques
et al, 1998). Our finding that mesenchymal staining with Gli1 in
some follicles extends from the positive region near the bulge
down the dermal sheath is consistent with these observations.
Secondly, SHH expression in developing hair follicles is differentially
expressed in the anterior epithelium of the hair follicle (Bitgood
and McMahon, 1995). Immunostaining of human fetal hair follicles
with the antibody to the C terminal Gli1 epitope stains mesenchymal
cells of fetal hair follicles and is differentially expressed towards one
side of the follicle. Although we have been unable to demonstrate
coexpression of SHH and Gli1 in human hair follicles for technical
reasons, the similarities between the pattern of Gli1 protein expres-
sion in this work and that reported for SHH support our conclusions
that Gli1 is being expressed in mesenchymal cells in adult human
skin.
Although previous studies using reverse transcriptase–PCR indi-
cate that Gli1 is differentially expressed in BCC this approach does
not provide reliable information about transcript abundance. In
view of the differences in the intensity of Gli1 immunostaining
between that seen in BCC islands compared with the ORS and
mesenchymal cells staining in normal skin we went on to quantitate
better the extent of the increase in Gli1 mRNA in BCC using
northern blot analysis with a Gli1-specific probe. The Gli1 probe
detected a 4 kb transcript in the BCC which is the same size as
that reported in Gli1 expressing glioblastoma and teratocarcinoma
lines (Kinzler et al, 1988). Comparison of transcript abundance
between the Tera-1 cell line and BCC samples relative to B-actin
indicates that the level of Gli1 in BCC is more than 30 times that
in normal skin compared with only a 4-fold increase in the Tera-
1 line. The weaker immunostaining for Gli1 protein in BCC
tumor islands relative to hair follicle ORS cells cannot be explained
by low expression of Gli1 mRNA in BCC and suggest that the
differences in the intensity of staining with the Gli1 antibodies may
be due to differences in epitope masking and/or conformation of
Gli1 between these two cell types.
The basis for the marked increase in Gli1 transcript abundance
in BCC is not known and the inability to culture BCC cells in vitro
makes it impossible to use conventional techniques to distinguish
between transcriptional activation and alterations in mRNA
stability. Liu and co-workers have suggested that the methylation
status of the core Gli1 promoter may influence Gli1 expression
(Liu et al, 1998). In order to look for indirect evidence that might
support the hypothesis that Gli1 is transcriptionally activated in
BCC we have also examined the methylation status of this region
in adult human tissues including leukocytes, normal skin, and BCC.
Southern blot analysis using a probe flanking the CpG island in
the core Gli1 promoter revealed that the promoter is unmethylated
in leukocytes, normal skin, and BCC. This observation suggests
that the lack of Gli1 gene expression in normal adult tissues is not
due to silencing of the promoter by DNA methylation.
In conclusion, the results from this study indicate that antibodies
directed against the N and C terminal domains of Gli1 detect Gli1
protein predominately in the cytoplasmic compartment of BCC
which suggests that the intracellular localization of Gli1 may play
a part in regulating Gli1 activity. It will be important in future
studies to determine why Gli1, which is believed to function as a
transcription factor is localized predominately in the cytoplasmic
compartment. Immunostaining of normal skin has shown that Gli1
protein is present in the ORS cells of normal hair follicles which
is consistent with recent work on Ptc1 expression in murine skin.
The presence of Gli1 protein in a subpopulation of mesenchymal
cells in both adult and fetal skin and the localization of these cells
in adult skin near the bulge region of the hair follicle suggest that
Gli1 may play a part in stem cell maintenance in human skin.
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